Antiinflammatory effect of telmisartan on chronic obstructive pulmonary disease: 8-isoprostane concentration in exhaled breath condensate
Abstract
Abstract
Aim. Chronic obstructive pulmonary disease (COPD) is a chronic, progressive, inflammatory disease. Oxidative stress and airway inflammation are its main pathophysiologic components. In this study, our aim was to investigate the effect of an angiotensin receptor blocker (ARB) telmisartan which also exerts antiinflammatory effects on inflammation and oxidative stress in COPD. Method. The study group consisted of 50 stable COPD patients including 25 telmisartan users. Exhaled breath condensate (EBC) samples of the cases were collected using an EBC collecting device (Ecoscreen, Jaeger, Germany). EBC samples were analyzed and 8-isoprostane levels were measured using an enzyme immunoassay method (Cayman Chemical Co. Michigan, USA). Results. Any intergroup difference as for mean age, distribution of gender and smoking were not found. In telmisartan users, and nonusers mean 8-isoprostane levels were 33.98 and 35.91 pg/mL, respectively with a statistically significant intergroup difference (p<0.001) Conclusion. We think that ARBs decrease oxidative stress and inflammation, and thus exert favourable effects on the pathophysiology and progression of COPD.
Keywords: Chronic obstructive pulmonary disease, oxidative stress, 8-isoprostane, angiotensin receptor blocker, telmisartan
Özet
Amaç. Kronik obstrüktif akciğer hastalığı (KOAH) kronik, ilerleyici, inflamatuar bir hastalıktır. Oksidatif stres ve havayolu inflamasyonu hastalığın ana patofizyolojik etkenleridir. Bu çalışmada bir anjiyotensin reseptör blokeri (ARB) olan telmisartan’ın KOAH’daki antiinflamatuar etkisini araştırmayı amaçladık. Yöntem. Çalışmaya 25’i telmisartan kullanan 50 KOAH hastası alındı. Hastaların yoğunlaştırılmış soluk havası (EBC) örnekleri EBC toplama cihazı kullanılarak toplandı (Ecoscreen, Jaeger, Germany). EBC örnekleri analiz edildi ve enzim immunoassay metodu (Cayman Chemical Co. Michigan, USA) kullanılarak 8-izoprostan düzeyleri ölçüldü. Bulgular. Her iki grup arasında ortalama yaş, cinsiyet ve sigara kullanımı açısından fark yoktu. Telmisartan kullanan ve kullanmayan grupta 8-izoprostan düzeyleri sırasıyla 33,98 ve 35,91 pg/mL olarak ölçüldü, iki grup arasındaki fark istatistiksel olarak anlamlı bulundu (p<0,001). Sonuç. ARB’lerin oksidatif stres ve inflamasyonu azaltarak hastalığın patofizyolojisi ve ilerleyişine olumlu etkileri olabilir.
Anahtar sözcükler: Kronik obstrüktif akciğer hastalığı, oksidatif stres, 8-izoprostan, anjiyotensin reseptör blokeri, telmisartan
Keywords
References
- Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-55.
- Global Initiative For Chronic Obstructive Lung Disease (GOLD) Updated 2008; 4: 24-30.
- Owen CA. Proteinases and Oxidants as Targets in the treatment of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2005; 2: 373-85.
- Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta 2005; 356: 22-34.
- Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998; 114: 1653-9.
- Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-7.
- Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane inexhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294-8.
- Inagami T, Senbonmatsu T. Dual effects of angiotensin II type 2 receptor on cardiovascular hypertrophy. Trends Cardiovasc Med 2001; 11: 324-8.
Details
Primary Language
English
Subjects
-
Journal Section
-
Authors
Abdülkerim Yılmaz
Handan İnönü Köseoğlu
Hakan Şıvgın
Mustafa Sağcan
Publication Date
June 27, 2014
Submission Date
April 2, 2013
Acceptance Date
-
Published in Issue
Year 2014 Volume: 36 Number: 2